Zydus Lifesciences Limited Press Release Apr 22 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the launch of Mirabegron Extended-Release Tablets in the US market. The company received final approval from the USFDA for these tablets and is among the first to launch the generic version. Mirabegron is used for treating overactive bladder symptoms and will be manufactured in Ahmedabad, India. This launch is expected to enhance access to the medication for patients in the US and support Zydus's growth plans in the market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 20 2024
- Press Release Apr 01 2024
- Press Release Mar 23 2024
- Press Release Mar 16 2024
- Press Release Mar 14 2024
Later from Zydus Lifesciences
- Press Release Apr 23 2024
- Press Release Apr 26 2024
- Press Release May 04 2024
- Press Release May 09 2024
- Press Release May 11 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences